📈 Markets & Finance risk-on · 1–3 years
A what‑if from the future

What if FTC eases pharma-merger blockade, unleashing pent-up bid pipeline?

A lighter-touch antitrust regime clears mid-size pharma deals that had been chilled, releasing a backlog of acquisitions and re-rating takeout-candidate biotechs.

35%
our model probability
over 1–3 years
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 35% · 90% range 2–68% · 13 analogues · measured class health 42% in 3 yr · 3% held back for the unknown
how we built this number — every step
Measured class rate — health ≈0.1843/yr → 42% in 3 yr42%
Analyst prior · editorial share 94% of the class40%
Pooled · weight 68%36%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)36%
Published35%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-on shock. A lighter-touch antitrust regime clears mid-size pharma deals that had been chilled, releasing a backlog of acquisitions and re-rating takeout-candidate biotechs. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Credit spreads ▼ · Risk appetite ▲ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Solana SOLon Hyperliquid 📈 chartCrypto▲ +0.7%
hist -8.97–+4.88% · other way -3.15% (n=9)
2MicroStrategy MSTRon Hyperliquid 📈 chartEquity▲ +0.6%
hist -9.15–+14.43% · other way +14.12% (n=12)
3Hyperliquid (HYPE) HYPEon HyperliquidCrypto▲ +0.6%
model prior · unmeasured
4Nasdaq 100 NDXon Hyperliquid 📈 chartIndex▲ +0.5%
hist +0.13–+0.6% · other way +1.07% (n=12)
5Ether ETHon Hyperliquid 📈 chartCrypto▲ +0.5%
hist -1.99–+2.31% · other way -4.92% (n=10)
6Bitcoin BTCon Hyperliquid 📈 chartCrypto▲ +0.4%
hist -4.16–+7.12% · other way -0.91% (n=11)
7Volatility (VIX) VIXon Hyperliquid 📈 chartVol▼ -0.4%
hist -2.13–+2.18% · other way +7.87% (n=12)
8S&P 500 SPXon Hyperliquid 📈 chartIndex▲ +0.3%
hist -0.08–+0.6% · other way -3.57% (n=12)
9Tech sector XLK 📈 chartEquity▲ +0.3%
hist -0.35–+0.96% · other way +0.76% (n=12)
10High-yield credit HYG 📈 chartRate▲ +0.2%
hist +-0.0–+0.23% · other way +0.41% (n=12)
11Coinbase COINon Hyperliquid 📈 chartEquity▲ +0.2%
hist -2.1–+2.63% · other way +13.61% (n=9)
12Semiconductors SMHon Hyperliquid 📈 chartEquity▲ +0.2%
hist -0.43–+0.94% · other way +1.47% (n=12)
13Financials XLF 📈 chartEquity▲ +0.1%
hist -0.33–+0.35% · other way +0.95% (n=12)
14Nvidia NVDAon Hyperliquid 📈 chartEquity▲ +0.1%
hist -2.36–+3.34% · other way +2.97% (n=12)

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
For a common-man portfolio: A typical stock-heavy portfolio should benefit. Stay invested; you can lean modestly into the beneficiaries below.
Also moves (not yet on Hyperliquid): Tech sector +0.3% · High-yield credit +0.2% · Financials +0.1%

Historical precedent — what analogous events actually did

Across 13 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 Human Genome Project completed 2003-04 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
SOL SOLSHORT-9.2% · 5d -9.6%79%10 0.43⚠ differs
SPX SPXLONG+0.4% · 5d +1.0%66%13 0.29✓ matches cascade
US dollar DXYSHORT-0.6% · 5d -0.6%69%13 0.28·
Bitcoin BTCLONG+7.0% · 5d -5.3% ↺ fades62%12 0.23✓ matches cascade
XLF XLFSHORT-0.5% · 5d -1.1%60%13 0.16⚠ differs
High-yield credit HYGSHORT-0.1% · 5d -0.2%62%12 0.15⚠ differs
SMH SMHLONG+0.8% · 5d +1.0%60%13 0.14✓ matches cascade
MSTR MSTRLONG+14.6% · 5d +0.1%57%13 0.13✓ matches cascade
Gold XAULONG+0.9% · 5d +0.2%57%13 0.11·
NDX NDXLONG+0.2% · 5d -0.4% ↺ fades54%13 0.06✓ matches cascade
ETH ETHSHORT-2.5% · 5d -7.2%54%10 0.06⚠ differs
10y yield DGS10LONG+4bp · 5d 0bp ↺ fades54%13 0.06·
XLK XLKLONG+0.7% · 5d +0.0%51%13 0.02✓ matches cascade
NVDA NVDALONG+3.4% · 5d -2.1% ↺ fades51%13 0.02✓ matches cascade

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.